Launch week offerEnds in00h00m00s
annual Promonthly Pro
Padma Sheila Rajagopal
Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (11)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2025
Year:
2025
Year:
2025
Purpose: Black women experience the highest breast cancer mortality rate compared to women of other racial/ethnic groups. To gain a deeper understanding of breast cancer heterogeneity across diverse populations, we examined a VEGF-hypoxia gene expression signature in breast tumors from women of diverse ancestry. Experimental Design: We developed a NanoString nCounter gene expression panel and applied it to breast tumors from Nigeria (n=182) and the University of Chicago (n=161). We also analyzed RNA sequencing data from Nigeria (n=84) and TCGA datasets (n=863). Patient prognosis was analyzed using multiple datasets. Results: The VEGF-hypoxia signature was highest in the basal-like subtype compared to other subtypes, with greater expression in Black women compared to White women. In the TCGA dataset, necrotic breast tumors had higher scores for the VEGF-hypoxia signature compared to non-necrosis tumors (p<0.001), with the highest proportion in the basal-like subtype. Furthermore, necrotic breast tumors have higher scores for the proliferation signature, suggesting an interaction between the VEGF-hypoxia signature, proliferation and necrosis. T cell gene expression signatures also correlated with the VEGF-hypoxia signature when testing all tumors in the TCGA dataset. Lastly, we found a significant association of the VEGF-hypoxia profile with poor outcomes when using all patients in the METABRIC (p<0.0001) and SCAN-B datasets (p=0.002). Conclusions:These data provide further evidence for breast cancer heterogeneity across diverse populations and molecular subtypes. Interventions selectively targeting VEGF-hypoxia and the immune microenvironment have the potential to improve overall survival in aggressive breast cancers that disproportionately impact Black women in the African Diaspora.
Year:
2024
Year:
2024
Year:
2024
Collaborators (11)
Mya Roberson
University of North Carolina at Chapel Hill
Siddhartha Yadav
Associate Professor of Oncology
Mayo Clinic
Sridhar Hannenhalli
Senior Investigator
National Cancer Institute
Carlos Caldas
Professor
Hebrew University of Jerusalem
Christine Lovly
Professor and Division Chief, Thoracic Medical Oncology
Beckman Research Institute, City of Hope
Christina Lockwood
Professor
Washington University School of Medicine
Colin Pritchard
University of Washington
David Takeda
Principal Investigator
National Institutes of Health
Sanju Sinha
Assistant Professor
Sanford Burnham Prebys Medical Discovery Institute
Annette Kim
Director, Division of Diagnostic Genetics and Genomics
University of Michigan
Olufunmilayo I. Olopade
University of Chicago
Make your next move.
Prepare your application
Review drafts before you send them.